| Literature DB >> 28603652 |
Alessandro Tuzi1, Elena Bolzacchini1, Matteo B Suter1, Alice Giaquinto1, Antonio Passaro2, Stefania Gobba1, Ilaria Vallini1, Graziella Pinotti1.
Abstract
As the leading cause of death worldwide, lung cancer has proven itself incurable in the advanced stages. For early stages, endobronchial ultrasounds transbronchial needle aspiration (EBUS-TBNA) is now considered the standard to assess mediastinal lymph node, to define the multimodality therapeutic approach. In recent years, EBUS-TBNA has extended its use also in the metastatic and locally recurrent disease. New molecules, with specific mutations that give resistance to current target therapies, have made re-biopsy at disease progression an important assessment, with therapeutic and clinical implication. Here we present the oncologist's point of view on EBUS-TBNA in the staging process, at recurrence and progression.Entities:
Keywords: Endobronchial ultrasounds (EBUS); T790M; lung cancer; re-biopsy; review
Year: 2017 PMID: 28603652 PMCID: PMC5459872 DOI: 10.21037/jtd.2017.04.09
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895